Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Potential use of CC-5013 in the treatment of hematological malignancies

Dec. 17, 2002

Disappointing phase III preliminary results for CeaVac in colorectal cancer

Dec. 16, 2002

IDEC-114 reported safe and effective in refractory follicular lymphoma

Dec. 16, 2002

Minimal toxicity reported for SGN-30 in Hodgkin's disease and lymphoma

Dec. 13, 2002

MDX-060 has marked antitumor activity in CD30+ lymphoma-bearing mice

Dec. 11, 2002

Vasogen reports preliminary results from pilot study in CLL

Dec. 11, 2002

Good safety profile reported for IL-13-PE38QQR in malignant glioma

Dec. 10, 2002

Dendreon announces amended pivotal trial for Provenge prostate cancer vaccine

Dec. 9, 2002

Promising data reported for dendritic cell vaccine in GBM

Dec. 5, 2002

Potential use of TP-38 in recurrent malignant brain tumors

Dec. 4, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...